Brexit and the UK life science industry
Damon Culbert looks at Brexit and the UK life science industry with particular consideration to the impact of immigration. For many industry professionals, Britain’s plans to leave the European...
High Court ruling against Novartis and Bayer: Implications
Claudia Rubin and Tom Jaggs explore the implications of the High Court ruling against Novartis and Bayer for pharma.
High Court ruling against Novartis and...
NHS long-term plan: Growing importance of prevention medicine
“The challenge now is for the NHS to respond to this changing landscape and to focus on preventing as well as treating the conditions...
Have analytics been relegated to a reporting function?
Have business analytics been pushed to the background? Business information upgraded, smart CRM datasets, the Predictive Analytics silver bullet and other fairy tales.
Is Brexit good news for pharma?
James Burt, Executive Vice President EMENA, Accord Healthcare, asks whether Brexit will in fact present an opportunity for positive change in pharma and healthcare.
What do NHS changes mean for tech innovation?
Could changes at the top mean fresh opportunities for tech innovation?
Read this in the August issue of Pf Magazine.
For some time it has been...
At the heart of it: The vital role of pharmacies in community health
Read this in the August issue of Pf Magazine.
Community pharmacy has a clear role in promoting and supporting the public’s health. There’s an accessible...
Five ways blockchain is impacting healthcare
Blockchain is one of the most talked about technologies at the moment and boasts huge potential to transform how we deliver healthcare and revolutionise...
Brexit: What will it mean for the regulation of medicines?
What are the implications for the movement of medicines from and into the UK, post-brexit? Mark Quick, executive vice president of corporate development at Recipharm, comments on the current situation and the potential implications of the UK exiting the European Union (EU).
The five key areas to drive growth of UK’s pharmaceutical sector
These 5 things are what pharmaceutical companies should be focusing on to maximise their growth in the UK.
Latest articles
Drug firms admit to colluding to keep up prices of antidepressants
Drug firms admit to colluding in order to keep up prices of antidepressants according to the Competition and Markets Authority (CMA). Two suppliers of the...
Licensing status of Avastin updated by MHRA
The licensing status of Avastin has been updated by the Medicines and Healthcare products Regulatory Agency (MHRA). The update concerns the licensing status of Avastin (bevacizumab)...
PM Society Digital Award Winners 2019
Thursday 19th September saw the tenth PM Society Digital Awards take place at The Brewery in London. Around 500 guests sat down to dinner...
Popular articles
Nurofen launches a 24 hour ibuprofen pain relief patch
Nurofen announces the launch of the UK’s only 24 hour clinically proven pain relief patch containing ibuprofen. Despite body pain being among the most commonly...
Licensing status of Avastin updated by MHRA
The licensing status of Avastin has been updated by the Medicines and Healthcare products Regulatory Agency (MHRA). The update concerns the licensing status of Avastin (bevacizumab)...
PM Society Digital Award Winners 2019
Thursday 19th September saw the tenth PM Society Digital Awards take place at The Brewery in London. Around 500 guests sat down to dinner...
Poor diabetes control costs the NHS £3bn in avoidable treatment
New research finds that poor diabetes control costs the NHS £3bn in potentially avoidable hospital treatment in England. The findings, being presented at this year’s...
Drug firms admit to colluding to keep up prices of antidepressants
Drug firms admit to colluding in order to keep up prices of antidepressants according to the Competition and Markets Authority (CMA). Two suppliers of the...